Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2270/10/09: Allergan v Merz Pharma β€” β€œAt least as effective as Botox” claim based on non-inferiority studies

Merz’s exhibition claim that Xeomin was β€œat least as effective as Botox” was ruled misleading because the cited…

8 Mar 2026

Flynn Pharma: competitor disparagement in rep training and discussion about Abstral during Actiq promotion (AUTH/2316/5/10)

A palliative medicine consultant complained about an Actiq rep’s comments on competitor Abstral. The Panel found misleading/disparaging competitor…

8 Mar 2026

AUTH/3171/3/19: Health professional v Novartis β€” meeting attendance certificate (no breach)

A health professional alleged a rep used delivery of an attendance certificate to secure a follow-up meeting (Clause…

8 Mar 2026

Lundbeck/Teva: Azilect β€˜slowing progression’ messaging at World Parkinson’s Congress and unapproved patient-facing website link (AUTH/2394/3/11, AUTH/2395/3/11)

At a Parkinson’s congress, an HCP symposium invite went into patient bags and a stand promoted β€œslowing clinical…

8 Mar 2026

PMCPA AUTH/3089/9/18: Director v Merck Serono (Clinical trial disclosure) – Outwith scope / No breach

PMCPA case AUTH/3089/9/18 (Director v Merck Serono) concerned clinical trial disclosure. Under the 2016 ABPI Code it was…

8 Mar 2026

AUTH/2534/10/12: Anonymous v Roche – Alleged pressure and inducements linked to rheumatoid arthritis project (No breach)

Anonymous complaint alleged Roche pressured a hospital pharmacist to continue an RA project and provided drinks/money. Panel found…

8 Mar 2026

Bayer: late-night hotel bar drinks at ISTH congress ruled not β€œsubsistence” (breach Clause 19.1)

Anonymous HCP alleged late-night hotel bar entertaining at ISTH Amsterdam. Panel accepted Bayer account of 4 drinks bought…

8 Mar 2026

AUTH/2778/7/15: Merz v Ipsen – Dysport leavepieces and dose-ratio comparisons

Ipsen’s Dysport leavepieces compared dose ratios vs other BoNT-A products using SPC data and a 2012 systematic review.…

8 Mar 2026

Roche: Paid-for magazine β€œarticle” seen as public advertising for Herceptin and Avastin (AUTH/2098/2/08)

Roche admitted a paid-for page in a consumer breast cancer magazine promoted Herceptin and Avastin to the public.…

8 Mar 2026

AUTH/2830/3/16 Pharmacosmos v Vifor: Ferinject promotion found misleading and disparaging about Monofer safety

Vifor’s Ferinject materials and briefings were found to encourage comparative safety messaging that disparaged Monofer and misled HCPs,…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training